JAK/STAT信号通路在消化系统疾病中的研究进展

doi:10.3969/j.issn.1004-583X.2024.12.012

摘要/Abstract

摘要：

Janus激酶(Janus kinase,JAK)/信号转导子和转录活化子(signal transducer and activator of transcription,STAT)信号通路是多种细胞因子传递信号的普遍方式,并且对于平衡免疫与炎症反应具有决定性的影响。本文通过对JAK/STAT信号通路传导过程及其在消化系统中的作用进行概述,分析JAK/STAT信号通路在各类消化系统疾病的表达情况及调控机制,以期为消化系统疾病发病机制研究及治疗有所帮助。

关键词: 消化系统疾病, JAK/STAT信号通路, 炎症性肠病, 胃肠道肿瘤, 抑制剂

中图分类号:

陈颖新, 王韶轩. JAK/STAT信号通路在消化系统疾病中的研究进展[J]. 临床荟萃, 2024, 39(12): 1125-1130.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://huicui.hebmu.edu.cn/CN/10.3969/j.issn.1004-583X.2024.12.012

https://huicui.hebmu.edu.cn/CN/Y2024/V39/I12/1125

参考文献 55

[1]	Xue C, Yao Q, Gu X, et al. Evolving cognition of the JAK-STAT signaling pathway: Autoimmune disorders and cancer[J]. Signal Transduct Target Ther, 2023, 8(1):204.
[2]	Roskoski RJ. Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders[J]. Pharmacol Res, 2022, 183:106362.
[3]	Hu Q, Bian Q, Rong D, et al. JAK/STAT pathway: Extracellular signals, diseases, immunity, and therapeutic regimens[J]. Front Bioeng Biotechnol, 2023, 11:1110765.
[4]	Núñez P, Quera R, Yarur AJ. Safety of Janus kinase inhibitors in inflammatory bowel diseases[J]. Drugs, 2023, 83(4):299-314. doi: 10.1007/s40265-023-01840-5 pmid: 36913180
[5]	Assal A, Mapara MY. Janus kinase inhibitors and cell therapy[J]. Front Immunol, 2021, 12:740847.
[6]	Henry SP, Jorgensen WL. Progress on the pharmacological targeting of Janus pseudokinases[J]. J Med Chem, 2023, 66(16):10959-10990. doi: 10.1021/acs.jmedchem.3c00926 pmid: 37578217
[7]	Yang X, Yan H, Jiang N, et al. IL-6 trans-signaling drives a STAT3-dependent pathway that leads to structural alterations of the peritoneal membrane[J]. Am J Physiol Renal Physiol, 2020, 318(2):F338-F353.
[8]	Hu X, Li J, Fu M, et al. The JAK/STAT signaling pathway: From bench to clinic[J]. Signal Transduct Target Ther, 2021, 6(1):402.
[9]	Chen H, Bian A, Zhou W, et al. Discovery of the highly selective and potent STAT3 inhibitor for pancreatic cancer treatment[J]. ACS Cent Sci, 2024, 10(3):579-594.
[10]	Li YJ, Zhang C, Martincuks A, et al. STAT proteins in cancer: Orchestration of metabolism[J]. Nat Rev Cancer, 2023, 23(3):115-134.
[11]	Du W, Liu N, Zhang Y, et al. PLOD2 promotes aerobic glycolysis and cell progression in colorectal cancer by upregulating HK2[J]. Biochem Cell Biol, 2020, 98(3):386-395. doi: 10.1139/bcb-2019-0256 pmid: 31742425
[12]	Guo X, Jiang C, Chen Z, et al. Regulation of the JAK/STAT signaling pathway in spinal cord injury: An updated review[J]. Front Immunol, 2023, 14:1276445.
[13]	Liang D, Wang Q, Zhang W, et al. JAK/STAT in leukemia: A clinical update[J]. Mol Cancer, 2024, 23(1):25. doi: 10.1186/s12943-023-01929-1 pmid: 38273387
[14]	Goetsch A, D'Amico F, Allocca M, et al. Advances in pharmacotherapy for ulcerative colitis: A focus on JAK1 inhibitors[J]. Expert Opin Pharmacother, 2023, 24(7):849-861. doi: 10.1080/14656566.2023.2200931 pmid: 37038911
[15]	Luo Y, Alexander M, Gadina M, et al. JAK-STAT signaling in human disease: From genetic syndromes to clinical inhibition[J]. J Allergy Clin Immunol, 2021, 148(4):911-925. doi: 10.1016/j.jaci.2021.08.004 pmid: 34625141
[16]	Muller R. JAK inhibitors in 2019, synthetic review in 10 points[J]. Eur J Intern Med, 2019, 66:9-17. doi: S0953-6205(19)30182-7 pmid: 31178258
[17]	Glassman CR, Tsutsumi N, Saxton RA, et al. Structure of a Janus kinase cytokine receptor complex reveals the basis for dimeric activation[J]. Science, 2022, 376(6589):163-169. doi: 10.1126/science.abn8933 pmid: 35271300
[18]	Gilardi D, Gabbiadini R, Allocca M, et al. PK, PD, and interactions: The new scenario with JAK inhibitors and S1P receptor modulators, two classes of small molecule drugs, in IBD[J]. Expert Rev Gastroenterol Hepatol, 2020, 14(9):797-806.
[19]	Wang J, Zhao X, Wan YY. Intricacies of TGF-β signaling in Treg and Th17 cell biology[J]. Cell Mol Immunol, 2023, 20(9):1002-1022. doi: 10.1038/s41423-023-01036-7 pmid: 37217798
[20]	Caiazzo G, Caiazzo A, Napolitano M, et al. The use of JAK/STAT inhibitors in chronic inflammatory disorders[J]. J Clin Med, 2023, 12(8):2865.
[21]	Qin Z, Wang R, Hou P, et al. TCR signaling induces STAT3 phosphorylation to promote TH17 cell differentiation[J]. J Exp Med, 2024, 221(3):e20230683.
[22]	Wang X, Han C, Yang D, et al. STAT3 and SOX-5 induce BRG1-mediated chromatin remodeling of RORCE2 in Th17 cells[J]. Commun Biol, 2024, 7(1):10. doi: 10.1038/s42003-023-05735-9 pmid: 38172644
[23]	Hindmarch DC, Malashanka S, Shows DM, et al. Janus kinase inhibitors differentially inhibit specific cytokine signals in the mesenteric lymph node cells of inflammatory bowel disease patients[J]. J Crohns Colitis, 2024, 18(4):628-637.
[24]	Salas A, Hernandez-Rocha C, Duijvestein M, et al. JAK-STAT pathway targeting for the treatment of inflammatory bowel disease[J]. Nat Rev Gastroenterol Hepatol, 2020, 17(6):323-337. doi: 10.1038/s41575-020-0273-0 pmid: 32203403
[25]	van Gennep S, Fung I, Jong DC, et al. Histological outcomes and JAK-STAT signalling in ulcerative colitis patients treated with Tofacitinib[J]. J Crohns Colitis, 2024, 18(8):1283-1291.
[26]	Quiniou G, Andromaque L, Duclaux-Loras R, et al. Impaired reprogramming of the autophagy flux in maturing dendritic cells from crohn disease patients with core autophagy gene-related polymorphisms[J]. Autophagy, 2024, 20(8):1837-1853.
[27]	Neurath MF. Strategies for targeting cytokines in inflammatory bowel disease[J]. Nat Rev Immunol, 2024, 24(8):559-576. doi: 10.1038/s41577-024-01008-6 pmid: 38486124
[28]	Lovato P, Brender C, Agnholt J, et al. Constitutive STAT3 activation in intestinal T cells from patients with Crohn's disease[J]. J Biol Chem, 2003, 278(19):16777-16781. doi: 10.1074/jbc.M207999200 pmid: 12615922
[29]	Villanueva A. Hepatocellular carcinoma[J]. N Engl J Med, 2019, 380(15):1450-1462.
[30]	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249.
[31]	Park H, Lee S, Lee J, et al. Exploring the JAK/STAT signaling pathway in hepatocellular carcinoma: Unraveling signaling complexity and therapeutic implications[J]. Int J Mol Sci, 2023, 24(18): 13764.
[32]	Xiao Y, Li Y, Shi D, et al. MEX3C-mediated decay of SOCS3 mRNA promotes JAK2/STAT3 signaling to facilitate metastasis in hepatocellular carcinoma[J]. Cancer Res, 2022, 82(22):4191-4205. doi: 10.1158/0008-5472.CAN-22-1203 pmid: 36112698
[33]	Lin L, Chen Q. Yadanziolide A inhibits proliferation and induces apoptosis of hepatocellular carcinoma via JAK-STAT pathway: A Preclinical Study[J]. Biology (Basel), 2024, 13(7): 528.
[34]	Hashemi M, Sabouni E, Rahmanian P, et al. Deciphering STAT3 signaling potential in hepatocellular carcinoma: Tumorigenesis, treatment resistance, and pharmacological significance[J]. Cell Mol Biol Lett, 2023, 28(1):33. doi: 10.1186/s11658-023-00438-9 pmid: 37085753
[35]	Zhou Q, Tian W, Jiang Z, et al. A positive feedback loop of AKR1C3-mediated activation of NF-κB and STAT3 facilitates proliferation and metastasis in hepatocellular carcinoma[J]. Cancer Res, 2021, 81(5):1361-1374. doi: 10.1158/0008-5472.CAN-20-2480 pmid: 33361392
[36]	Li Y, Song Z, Han Q, et al. Targeted inhibition of STAT3 induces immunogenic cell death of hepatocellular carcinoma cells via glycolysis[J]. Mol Oncol, 2022, 16(15):2861-2880. doi: 10.1002/1878-0261.13263 pmid: 35665592
[37]	Ni Y, Low JT, Silke J, et al. Digesting the role of JAK-STAT and cytokine signaling in oral and gastric cancers[J]. Front Immunol, 2022, 13:835997.
[38]	Yang YL, Liu P, Li D, et al. Stat-3 signaling promotes cell proliferation and metastasis of gastric cancer through PDCD4 downregulation[J]. Kaohsiung J Med Sci, 2020, 36(4):244-249.
[39]	Huo C, Gu Y, Wang D, et al. STAT1 suppresses the transcriptional activity of TRIM21 in gastric cancer[J]. J Cancer Res Clin Oncol, 2023, 149(17):15335-15348. doi: 10.1007/s00432-023-05307-8 pmid: 37639009
[40]	Suresh RN, Jung YY, Mohan CD, et al. A new triazolyl-indolo-quinoxaline induces apoptosis in gastric cancer cells by abrogating the STAT3/5 pathway through upregulation of PTPεC[J]. Drug Dev Res, 2023, 84(8):1724-1738.
[41]	Zhou J, Li T, Chen H, et al. ADAMTS10 inhibits aggressiveness via JAK/STAT/c-MYC pathway and reprograms macrophage to create an anti-malignant microenvironment in gastric cancer[J]. Gastric Cancer, 2022, 25(6):1002-1016. doi: 10.1007/s10120-022-01319-4 pmid: 35925524
[42]	Ghasemian A, Omear HA, Mansoori Y, et al. Long non-coding RNAs and JAK/STAT signaling pathway regulation in colorectal cancer development[J]. Front Genet, 2023, 14:1297093.
[43]	Heichler C, Scheibe K, Schmied A, et al. STAT3 activation through IL-6/IL-11 in cancer-associated fibroblasts promotes colorectal tumour development and correlates with poor prognosis[J]. Gut, 2020, 69(7):1269-1282. doi: 10.1136/gutjnl-2019-319200 pmid: 31685519
[44]	Liu J, Xing R, Shao J, et al. Relationship between MUC4 variants and metastatic recurrence in colorectal cancer[J]. Int J Gen Med, 2023, 16:5077-5087. doi: 10.2147/IJGM.S437957 pmid: 37942474
[45]	You AB, Yang H, Lai CP, et al. CMTR1 promotes colorectal cancer cell growth and immune evasion by transcriptionally regulating STAT3[J]. Cell Death Dis, 2023, 14(4):245. doi: 10.1038/s41419-023-05767-3 pmid: 37024465
[46]	Wei XH, Liu YY. Potential applications of JAK inhibitors, clinically approved drugs against autoimmune diseases, in cancer therapy[J]. Front Pharmacol, 2023, 14:1326281.
[47]	Taylor PC, Choy E, Baraliakos X, et al. Differential properties of Janus kinase inhibitors in the treatment of immune-mediated inflammatory diseases[J]. Rheumatology (Oxford), 2024, 63(2):298-308.
[48]	Sandborn WJ, Ghosh S, Panes J, et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis[J]. N Engl J Med, 2012, 367(7):616-624.
[49]	Sandborn WJ, D'Haens GR, Sands BE, et al. Tofacitinib for the treatment of ulcerative colitis: An integrated summary of up to 7.8 years of safety data from the global clinical programme[J]. J Crohns Colitis, 2023, 17(3):338-351.
[50]	Garrido I, Lopes S, Macedo G. Hit the road JAK! The role of new oral treatment in inflammatory bowel disease[J]. Inflamm Bowel Dis, 2021, 27(12):2010-2022. doi: 10.1093/ibd/izab037 pmid: 33742651
[51]	Shawky AM, Almalki FA, Abdalla AN, et al. A comprehensive overview of globally approved JAK inhibitors[J]. Pharmaceutics, 2022, 14(5): 1001.
[52]	Loftus EJ, Panés J, Lacerda AP, et al. Upadacitinib induction and maintenance therapy for Crohn's disease[J]. N Engl J Med, 2023, 388(21):1966-1980.
[53]	Guo J, Wang LY, Wu J, et al. The JAK2 inhibitor AG490 regulates the Treg/Th17 balance and alleviates DSS-induced intestinal damage in IBD rat[J]. Clin Exp Pharmacol Physiol, 2020, 47(8):1374-1381.
[54]	Wang D, Yin J, Dong R, et al. Inhibition of Janus kinase-2 signalling pathway ameliorates portal hypertensive syndrome in partial portal hypertensive and liver cirrhosis rats[J]. Dig Liver Dis, 2015, 47(4):315-323.
[55]	Lin Z, Liu Y, Xu T, et al. STAT3-mediated promoter-enhancer interaction up-regulates inhibitor of DNA binding 1 (ID1) to promote colon cancer progression[J]. Int J Mol Sci, 2023, 24(12): 10041.

JAK/STAT信号通路在消化系统疾病中的研究进展

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 55

相关文章 15

编辑推荐

Metrics

本文评价

[1]	陈瑾, 吕鸿雁, 刘晗, 刘建宁, 卢佳配, 张金巧. 靶向BCMA的嵌合抗原受体T细胞治疗三重难治性多发性骨髓瘤的研究进展[J]. 临床荟萃, 2023, 38(7): 654-658.
[2]	李阳, 默峰, 辛志飞, 王倩, 邓新娜. 特殊临床表现多系统免疫相关不良事件1例[J]. 临床荟萃, 2023, 38(7): 633-637.
[3]	彭灵智, 祝成楼, 刘天祥. 超级增强子:肿瘤治疗的新靶点[J]. 临床荟萃, 2023, 38(3): 273-278.
[4]	郭雨, 李永东. ARNI在高血压治疗中的研究进展[J]. 临床荟萃, 2023, 38(2): 181-184.
[5]	陈珺. 钠-葡萄糖转运蛋白2抑制剂在2型糖尿病患者中用药安全性的研究进展[J]. 临床荟萃, 2023, 38(11): 1042-1047.
[6]	叶倩, 凌志, 刘申香, 路国涛, 殷旭东. 糖皮质激素对晚期肿瘤患者免疫疗效影响的Meta分析[J]. 临床荟萃, 2022, 37(7): 591-598.
[7]	李晴, 钟文, 刘思强, 陈愉生, 李鸿茹. PD-1/PD-L1抑制剂治疗非小细胞肺癌脑转移患者疗效的Meta分析[J]. 临床荟萃, 2022, 37(5): 400-405.
[8]	李姮, 李永辉, 孙小强, 王琳, 何峰. 窦性心律慢性心力衰竭患者抗凝治疗安全性及有效性系统评价[J]. 临床荟萃, 2022, 37(5): 406-411.
[9]	程霞, 程兰兰, 张鹏伟, 马志刚. 钠-葡萄糖协同转运蛋白2抑制剂肾脏保护作用的研究进展[J]. 临床荟萃, 2022, 37(5): 467-471.
[10]	黄业鸿, 刘改芳, 忻晨曦, 赵云红, 吴婧. 质子泵抑制剂大剂量二联与铋剂四联在幽门螺杆菌根除治疗中的疗效比较[J]. 临床荟萃, 2022, 37(3): 230-233.
[11]	黄佳圆, 潘半舟, 纪红, 梅静峰, 范朝晖, 周云. 帕博利珠单抗致剥脱性皮炎1例的临床诊治并同期应用帕博利珠单抗44例皮肤毒性分析[J]. 临床荟萃, 2022, 37(2): 150-154.
[12]	邱建美, 王德峰. 恩格列净治疗2型糖尿病的研究现状[J]. 临床荟萃, 2022, 37(2): 170-173.
[13]	王润青, 王谦, 廖健雄. SGLT2抑制剂对2型糖尿病患者心血管结局影响的网状meta分析[J]. 临床荟萃, 2022, 37(12): 1061-1073.
[14]	张磊, 娄海东, 智昱, 亓树莹. PCSK9抑制剂对动脉粥样硬化性心血管疾病有效性及安全性的meta分析[J]. 临床荟萃, 2022, 37(12): 1074-1080.
[15]	朱素华, 徐圣秋. 基质金属蛋白酶抑制剂在糖尿病视网膜病变的研究进展[J]. 临床荟萃, 2022, 37(12): 1148-1152.